# YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China

> **NCT02710708** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 1921 (actual)

## Conditions studied

- Contraception

## Interventions

- **DRUG:** EE20/DRSP (YAZ, BAY86-5300)

## Key facts

- **NCT ID:** NCT02710708
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-27
- **Primary completion:** 2018-07-03
- **Final completion:** 2018-07-03
- **Target enrollment:** 1921 (ACTUAL)
- **Last updated:** 2019-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02710708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02710708, "YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02710708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*